Repligen to Acquire BioLife Solutions in Mixed Stock-and-Cash Transaction Valued at $11.25 Per Share Plus Stock

Merger Structure and Regulatory Pathway

The transaction is structured as a two-step merger process. In the first step, Repligen's wholly owned subsidiary Bravo Merger Sub I, Inc. will merge with and into BioLife, with BioLife surviving as a direct, wholly owned subsidiary of Repligen. Immediately thereafter, in the second step, BioLife will merge with and into another Repligen subsidiary, Bravo Merger Sub II, LLC, with Merger Sub 2 surviving as a direct, wholly owned subsidiary of Repligen. This two-step structure is a common approach in merger transactions designed to facilitate various aspects of the transaction integration.

The merger is subject to multiple closing conditions that must be satisfied or waived before the transaction can be completed. These conditions include the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The parties must also obtain consents required under antitrust laws of specified jurisdictions. Additionally, the shares of Repligen common stock to be issued in the transaction must be approved for listing on The Nasdaq Stock Market, and the U.S. Securities and Exchange Commission must declare effective the Registration Statement on Form S-4 that Repligen will file.

Merger Consideration Structure and Stock Treatment

Each outstanding share of BioLife common stock (excluding treasury shares, shares held by Repligen or its subsidiaries, and shares subject to properly exercised appraisal rights) will be converted into the right to receive $11.25 in cash plus 0.1442 validly issued, fully paid and nonassessable shares of Repligen common stock. No fractional shares of Repligen common stock will be issued; instead, BioLife stockholders will receive cash in lieu of any fractional shares as specified in the merger agreement. The cash consideration will be paid without interest at the effective time of the first merger.

The filing states that all shares of BioLife common stock issuable pursuant to the treatment of equity awards will be converted automatically into the right to receive the merger consideration at the effective time of the first merger. Stockholders who receive fractional share entitlements will have those amounts settled in cash rather than receiving partial shares, simplifying the post-closing settlement process for both parties.

Accelerated Vesting of BioLife Equity Awards

The merger agreement provides for the acceleration and conversion of various forms of BioLife equity compensation immediately prior to the effective time of the first merger. All outstanding BioLife stock options, whether vested or unvested, will become fully vested and will be cancelled in exchange for a cash payment. The payment to option holders is calculated as the number of shares subject to the options minus a number of shares equal in value to the aggregate exercise price, net of any shares equal in value to applicable tax withholdings.

Restricted stock unit awards with time-based vesting ("BioLife RSUs") will accelerate vesting in full and be settled in shares of BioLife common stock, net of tax withholdings. Awards with performance-based vesting ("BioLife PSUs") will also accelerate vesting in full and be settled based on the greater of target or actual achievement of applicable performance goals as measured as of the latest practicable date prior to the first merger effective time, also net of tax withholdings. Outstanding unvested restricted stock awards ("BioLife RSAs") will similarly accelerate vesting in full and be released to holders in shares of BioLife common stock, net of applicable tax withholdings.

Stockholder Approval and Board Endorsement

The boards of directors of both Repligen and BioLife have approved the merger agreement and the transactions contemplated by it. The completion of the merger is conditioned upon approval by the holders of a majority of the outstanding shares of BioLife common stock entitled to vote at a duly held stockholders' meeting. BioLife will be required to hold a stockholders' meeting to seek this approval from its shareholders. The disclosure does not specify a date for the stockholders' meeting or provide information regarding management recommendations, but confirmation of board approval from both parties signals alignment between the companies' leadership on the transaction.

The merger agreement also includes customary representations, warranties, and covenants from all parties to the transaction. BioLife has covenanted to use reasonable efforts to conduct its business in the ordinary course consistent with past practice and to preserve substantially intact its present business organization and material assets, subject to certain exceptions and to written consent from Repligen. Similarly, Repligen has made covenants regarding the conduct of its business during the period between execution of the merger agreement and consummation of the mergers, subject to exceptions and to written consent from BioLife.

Expected Timing and Customary Conditions

The parties expect the mergers to be completed in the fourth quarter of 2026, subject to satisfaction of customary closing conditions. The company did not disclose this figure in the filing regarding the total transaction value or implied enterprise value. The timeline suggests a relatively expedited process if all regulatory approvals and conditions are satisfied on schedule. However, the actual completion date could be affected by regulatory review timelines, stockholder voting procedures, and other factors beyond the parties' control.

Among the closing conditions are the absence of any adverse law or order that would restrain, enjoin, make illegal, or otherwise prohibit the consummation of the mergers. The accuracy of representations and warranties made by each party (subject to certain materiality exceptions) must also be confirmed at closing. Additionally, neither Repligen nor BioLife may experience a continuing material adverse effect for the transaction to proceed. These standard conditions provide both parties with protections should circumstances change materially prior to closing.

Merger Agreement Communications and Public Disclosure Process

The filing was submitted under Rule 425 of the Securities Act, which permits written communications relating to a proposed business combination before the filing of a registration statement. The submission of this Form 8-K indicates that both companies are making an orderly disclosure of the transaction to the investing public and regulatory authorities. Repligen will be required to file a Registration Statement on Form S-4 with the SEC, which will contain the proxy statement and prospectus for the transaction. The SEC must declare this registration statement effective before the merger can be completed.

This public disclosure process ensures that all stockholders of both companies have access to material information about the transaction and its terms. The proxy statement/prospectus will provide detailed financial, operational, and risk information to help BioLife stockholders make an informed decision on the merger proposal at the stockholders' meeting. Repligen shareholders will also receive information about the transaction and the implications for Repligen's ownership structure, given that the acquisition will result in the issuance of new shares.

Conditions Related to Antitrust and Securities Regulation

Beyond the Hart-Scott-Rodino waiting period expiration, the parties must obtain consents required under antitrust laws in specified jurisdictions. The disclosure does not detail which specific jurisdictions are contemplated, but the reference to multiple antitrust regimes suggests that both companies may have international operations or customer bases that could trigger antitrust review in jurisdictions outside the United States. The parties have committed to using reasonable best efforts to cause the conditions of the mergers to be satisfied and to consummate the mergers.

Repligen's common stock must also be approved for listing on The Nasdaq Stock Market in connection with the shares to be issued in the merger. The SEC must declare effective the Registration Statement on Form S-4 that will be filed by Repligen and will contain the proxy statement/prospectus. These regulatory approvals are standard preconditions in transactions involving public company stock issuance and ensure that all necessary securities law compliance is achieved before closing.

Implications for Repligen Shareholders and Capital Structure

The transaction will result in Repligen issuing new shares of common stock to BioLife shareholders, diluting the ownership percentage of existing Repligen shareholders. The company did not disclose the number of BioLife shares outstanding in the filing, so the exact dilutive impact cannot be quantified from the information provided. Existing Repligen stockholders should review the proxy statement/prospectus when it is filed to understand the fully diluted ownership impact and other financial implications of the acquisition.

The cash component of the consideration ($11.25 per BioLife share) will require Repligen to have sufficient liquidity or access to financing to complete the transaction. The filing does not disclose the total purchase price, the source of funding for the cash consideration, or whether any financing arrangements have been secured. Investors in Repligen may want to monitor future disclosures and earnings reports for information about how the company plans to fund the cash portion of the merger consideration.

Material Adverse Effect Protection and Business Continuation

A key closing condition for both parties is the absence of a continuing material adverse effect with respect to each of Repligen and BioLife. This protection allows either party to terminate the merger agreement if circumstances change materially in ways that would significantly impact the value of the transaction. The merger agreement defines the scope of what constitutes a material adverse effect, though the specific definition is not provided in this disclosure. Both companies have committed to continuing to operate their businesses in the ordinary course during the period between signing and closing.

The ordinary course operating covenants mean that BioLife cannot take certain specified actions without Repligen's written consent, and Repligen faces similar restrictions regarding actions requiring BioLife consent. These covenants are designed to preserve the value of each company and prevent actions that might undermine the transaction's rationale or terms. The filing indicates that the merger agreement includes a detailed list of prohibited actions for each party, though the specific actions are not enumerated in this announcement.